12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

E2609: Phase I data

The double-blind, placebo-controlled, U.S. Phase I A001-001 trial in 73 healthy volunteers showed that single doses of 5-800 mg E2609 led to dose-dependent reductions in plasma ...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >